SCHEMBL5645475

SCHEMBL5645475

O=C(Nc1ccc(O)nc1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.72
KCNQ2 O43526 1/20 0.72
KCNE1 P15382 1/20 0.72
KCNQ1 P51787 1/20 0.72
TRPV1 Q8NER1 4/20 0.59
PTGS1 P23219 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
MAPT P10636 2/20 0.58
STAT3 P40763 1/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
EPHX2 P34913 1/20 0.58
RORC P51449 1/20 0.57
DEGS1 O15121 1/20 0.57
TNF P01375 1/20 0.56
NOD1 Q9Y239 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KIT P10721 1/20 0.55
MEN1 O00255 1/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647238 0.86 KCNQ3 (0.69) KCNQ3KCNQ2KCNE1KCNQ1NPC1
SCHEMBL14339875 0.84 KCNQ3 (1.00) KCNQ3KCNQ2KCNE1KCNQ1TRPV1
SCHEMBL7513604 0.82 TRPV1 (0.83) KCNQ3KCNQ2KCNE1KCNQ1TRPV1
SCHEMBL5649558 0.81 KCNQ3 (0.74) KCNQ3KCNQ2KCNE1KCNQ1SMN1; SMN2
SCHEMBL5648744 0.81 KCNQ3 (0.69) KCNQ3KCNQ2SMN1; SMN2MAPTNPC1
SCHEMBL14516640 0.80 KCNQ3 (0.74) KCNQ3KCNQ2KCNE1KCNQ1TRPV1
SCHEMBL2064051 0.79 TRPV1 (0.73) KCNQ3KCNQ2KCNE1KCNQ1TRPV1
SCHEMBL2923145 0.79 TRPV1 (0.73) KCNQ3KCNQ2KCNE1KCNQ1TRPV1
SCHEMBL38658963 0.78 MAPT (0.61) KCNQ3KCNQ2KCNE1KCNQ1TRPV1
SCHEMBL5646450 0.78 RAB9A (0.69) SMN1; SMN2MAPTNPC1RAB9ADEGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL KCNQ3 4724/4885KCNQ2 4759/4885KCNE1 4754/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL KCNQ3 4500/4885KCNQ2 4591/4885KCNE1 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.